Hatim Husain, MD

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Hatim Husain, MD, discusses the utility of liquid biopsy versus tissue biopsy in non–small cell lung cancer.

Hatim Husain, MD, assistant professor of Medicine, Moores Cancer Center, University of California, San Diego, discusses plasma-based testing in lung cancer.

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

Hatim Husain, MD, assistant professor of Hematology-Oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR-mutated NSCLC.

With careful attention to detail and conscientious efforts, clinical skills are likely to be transferable from clinical education to meeting research goals.